Septin-7 Antibody, Tissue Immunofluorescence Titer, Spinal Fluid
Use
This test is useful for detecting septin-7 IgG in cerebrospinal fluid (CSF) specimens. Positive results can help diagnose neurological phenotypes such as encephalopathy, myelopathy, encephalomyelopathy, painful myelopolyradiculopathy, and episodic ataxia. Septin-7 IgG is associated with autoimmune diseases of the central nervous system, certain cancers, and a positive response to immunotherapy.
Special Instructions
The test is only orderable as a reflex. Accurate diagnosis may require correlation with other diagnostic information, and seropositivity implies autoimmunity within the central nervous system. Cell-binding assays for septin-7 IgG may be necessary for confirmation.
Limitations
Negative results do not exclude neurological autoimmunity or the presence of cancer. Some cross-reactivity with non-neuronal antibodies may occur, but these can often be eliminated by serological absorption. Interpretation must consider potential interference by coexistent non-specific antibodies.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay)
Biomarkers
LOINC Codes
- 101457-0
- 101457-0
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
1.5 mL
Minimum Volume
Not provided
Container
Sterile vial
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |